Cost-effectiveness of HPV-based versus VIA-based cervical cancer screening among women living with HIV in Masaka District, Uganda

13 Jul 20264 min read0 viewsVerified Feed

GIST (Key Takeaways)

Cervical cancer is a leading cause of cancer-related mortality among women in Uganda, with women living with HIV (WLHIV) at disproportionate risk due to immunosuppression-driven persistence of human papillomavirus (HPV). Despite national guidelines recommending HPV testing as the preferred screening modality, resource constraints drive continued reliance on visual inspection with acetic acid (VIA), and locally generated cost-effectiveness evidence for WLHIV is limited. This study evaluated the cost-effectiveness of HPV-based versus VIA-based cervical cancer screening among WLHIV in Masaka District, Uganda.
A provider-perspective cost-effectiveness analysis was conducted using data from January to December 2024. Costs were estimated using an ingredient-based micro-costing approach capturing personnel, consumables, equipment, and overheads. A total of 1,732 WLHIV aged 25-65 years attended Uganda Cares Masaka: 1,404 screened by HPV-based testing and 326 by VIA.
A decision-tree model simulated screening pathways, costs, and outcomes. The primary effectiveness measure was the number of positive cases detected and treated; the incremental cost-effectiveness ratio (ICER) was the primary economic outcome. Deterministic one-way and probabilistic (1,000 Monte Carlo iterations) sensitivity analyses were conducted.

Clinical Editorial

medRxiv (Clinical Preprints) published a clinical update in Research Highlights on 13 Jul 2026.

The item focuses on Cost-effectiveness of HPV-based versus VIA-based cervical cancer screening among women living with HIV in Masaka District, Uganda.

Review the original article for the full source wording and details.